How Common is Microscopic Haematuria?
Very. While the text-book average is often cited as 5–10%, the prevalence of microscopic haematuria (MH) is highly variable depending on how “healthy” or “screened” a population is.
Many of these patients do not need investigating – and have no significant urinary tract disease. This article will help you decide who needs investigating.
-
General Prevalence: Studies of healthy volunteers show a range from 2.4% to 31.1%.
-
Clinical Significance: For many, a small amount of blood (defined as >5 red blood cells per high-power field) is a “physiological” baseline rather than a sign of disease.
-
Referral Impact: Haematuria remains the “bread and butter” of urology, accounting for over 20-25% of all urological referrals.
2. Categorizing the Causes: Surgical vs. Medical
When blood is detected, clinicians must distinguish between “surgical” (structural/urological) and “medical” (nephrological) origins.
Surgical (Urological) Causes
These typically involve the “plumbing” of the urinary tract and may require procedural intervention:
-
Malignancy (~3%): Includes bladder, kidney, and ureteral cancers.
-
Infection: UTIs, prostatitis, or urethritis (the most common transient causes).
-
Calculi (Stones): Kidney or bladder stones can irritate the lining of the tract.
-
Prostatic Issues: Benign Prostatic Hyperplasia (BPH) is a leading cause in older men.
-
Anatomical: Congenital abnormalities or acquired strictures.
Medical (Nephrological) Causes
These involve the kidney’s filtration system (the glomerulus) and often present with other markers like proteinuria:
-
Glomerulonephritis: Such as IgA Nephropathy or Post-streptococcal GN.
-
CKD Indicators: Chronic tubulointerstitial disease.
-
Thin Basement Membrane Disease: A benign, often familial condition where the kidney filter is simply “leaky.”
3. The 2025 Risk-Stratification Model
Modern medicine has shifted away from “testing everyone” to a risk-based approach to avoid the harms of over-investigation (radiation, invasive scopes, and high costs).
The 2025 AUA/SUFU Guidelines now categorise patients into three tiers:
| Risk Category |
Key Criteria Examples |
Malignancy Risk |
Recommended Action |
| Low / Negligible |
Women <60, Men <40, <10 RBC/HPF, Non-smokers |
<0.5% |
Repeat urinalysis in 6 months; no immediate scope. |
| Intermediate |
Age 40–59, 11–25 RBC/HPF, 10–30 pack-year smoking |
~1–3% |
Cystoscopy and Renal Ultrasound. |
| High |
Age 60+, >25 RBC/HPF, >30 pack-year smoking, or History of Gross Haematuria |
>6% |
Cystoscopy and CT Urogram (axial imaging). |
4. Why “More Testing” Isn’t Always Better
The evaluation of MH involves a delicate balance. While we want to catch the 3% of cancers, the other 97% face potential harms:
-
Procedural Risk: Cystoscopy (inserting a camera) can cause discomfort or UTIs.
-
Radiation Exposure: CT Urograms involve significant radiation.
-
False Positives: Leading to “incidentalomas”—findings that aren’t dangerous but lead to more unnecessary surgeries.
-
Guideline Adherence: Historically, adherence to these rules has been poor, but the 2025 updates emphasise Shared Decision Making (SDM), allowing patients in the low and intermediate groups to weigh the risks of a “missed” diagnosis against the harms of the workup.
Key takeaway: If you are “Low Risk,” a single positive test might be a fluke. If you are “High Risk,” or have ever seen visible blood (Gross Haematuria), the risk of cancer jumps significantly, and a full workup is mandatory.